Artelo Biosciences, Inc. announced that the research group working with Steven Laviolette, Ph.D., Scientific Advisor at Artelo Biosciences and Professor in the Schulich School of Medicine at the University of Western Ontario, Canada, will be presenting at Neuroscience 2023. The conference will be hosted by the Society for Neuroscience and held November 11-15, 2023 at the Walter E. Washington Convention Center in Washington, D.C. Neuroscience 2023 is the source of emerging news on brain science and health, with 25,000 neuroscience researchers and clinicians expected in attendance. One poster presentation will discuss Artelo's Fatty Acid Binding Protein 5 (FABP5) inhibitor, ART26.12, and will provide an overview of ART26.12's ability to modulate key signaling pathways that control depressive and anxiety-related behaviors.

Another poster will present work on Artelo's proprietary cocrystal of cannabidiol and tetramethylpyrazine, ART12.11, which has demonstrated improved efficacy and bioavailability compared to cannabidiol alone in a model of anxiety and depression. Artelo plans to file an IND (Investigational New Drug) application with the Food and Drug Administration (FDA) in the first half of 2024 to develop ART26.12 for the treatment of neuropathic pain, which follows previously announced FDA Pre-IND meeting earlier this year. ART26.12 has demonstrated a positive effect in numerous animal models of painful neuropathies, including chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy.

Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. Various inhibitors of FABPs may be particularly useful for the treatment of specific cancers, neuropathic and nociceptive pain, and anxiety disorders. ART26.12, Artelo's lead FABP inhibitor compound, is a selective inhibitor of FABP5.

While developing its lead molecule for chemotherapy-induced peripheral neuropathy, additional compounds from extensive library of potent and selective inhibitors of FABPs have been identified and selected for advancement towards regulatory-enabling studies in cancer and other areas of high-unmet need where inhibition of FABPs show significant promise. ART12.11 is a proprietary cocrystal composition of cannabidiol (CBD). It is isolated as a single crystalline form that offers biopharmaceutic advantages over compositions of CBD that exhibit solid polymorphism (i.e., the ability to manifest different forms).

Preclinical studies of ART12.11 have exhibited superior pharmacokinetics and improved efficacy compared to other forms of CBD. With superior pharmaceutical properties and preclinical results, Artelo believes a more consistent and improved bioavailability profile may ultimately lead to improved safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. Painful Neuropathies: Peripheral neuropathy refers to a condition in which there is damage to the peripheral nerves.

These nerves are responsible for transmitting signals between the central nervous system and the rest of the body. CIPN is a common and often painful complication of cancer therapies, sometimes resulting in reduction orcessation of treatment. No currently approved treatment exists for CIPN.

Diabetic neuropathy refers to a type of nerve damage that occurs as a complication of diabetes. It is caused by long-term high blood sugar levels, which can lead to damage of the blood vessels and can lead to the blood vessels and have the ability to reduce the blood vessels.